Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Immuno-Oncology Combination Therapy: Implications For Major Pharma

Reporter: Aviva Lev-Ari, PhD, RN

J.P.Morgans report The Next-Wave of Immuno-Oncology Thoughts On Combination Therapy and The Implications For Major Pharma comprises an Appendix. On pages 64-67 in a Table format all Immuno-Oncology Drugs are classified by Clinical Trial Phase, by Major Pharma developer, indication and Mechanism of Action. These pages are a representation of the global Pharmaceutical market development of Immuno-Oncology drugs and the Combination Drug Therapy demonstrating prospects in tumor cell therapy and potential cure of cancer by type.

The Next-Wave of Immuno-Oncology Thoughts On Combination Therapy and The Implications For Major Pharma

J.P.Morgan

US & EU Equity Research December, 2015

http://jpmorgan.metameetings.com/confbook/healthcare16/stash/misc/IO%20Combos.pdf

• Next Generation I/O Agents : Our EU Pharma Key Takeaways
• PD-1/PD-L1 Monotherapy Has Shown Compelling Activity Across Multiple Tumor Types
• Rationale for Combination I/O Therapies
• I/O Combo Data in Melanoma and Lung Show Improvement Relative to Monotherapy
• Combo with chemotherapy has also shown an improvement relative to monotherapy
• I/O Combinations Have the Potential to Modulate Various Steps Leading to the Elimination of Cancer Cells
• The Combination I/O Likely Further Resets Landscape

SOURCE

http://jpmorgan.metameetings.com/confbook/healthcare16/stash/misc/IO%20Combos.pdf